By Donnie Yance
As a musician and composer, I’ve always been fascinated by the power of sound. We know sound waves can shatter glass, create beautiful music, and even help babies develop in the womb. But what if I told you that precisely controlled sound waves could also destroy cancer cells while leaving surrounding healthy tissue completely untouched?
This isn’t science fiction, it’s a revolutionary medical treatment called histotripsy. Think of it as ultra-precise microsurgery, but without a single incision. No scalpels. No radiation. Just carefully focused sound waves that work with remarkable precision.
What Does Histotripsy Mean?
The word histotripsy comes from the two Greek words for ‘tissue’ and ‘friction’, so it’s simply using sound waves to create friction in the tissues. A related technology is called High-Intensity Focused Ultrasound (HIFU). While both HIFU and histotripsy use ultrasound waves, they are not the same thing; histotripsy is a specific type of HIFU that primarily relies on mechanical tissue destruction through cavitation bubbles, whereas traditional HIFU uses heat to destroy tumor tissue, making histotripsy a non-thermal method of tissue destruction.
Breaking Down Histotripsy: Sound Surgery Made Simple
Imagine dropping a pebble into a pond. The ripples spread out in perfect circles. Now imagine being able to focus thousands of these ripples onto a single point, with such intensity that they can break down unwanted tissue while leaving everything else untouched. That’s essentially how histotripsy works.
First developed in 2003 at the University of Michigan, this breakthrough technology uses high-intensity ultrasound pulses – similar to the ones used in pregnancy scans, but much more powerful. The key difference? While traditional ultrasound lets doctors see inside your body, histotripsy can actually treat what’s inside.
How Does It Actually Work?
Imagine popping a bubble in slow motion – that’s surprisingly similar to how histotripsy treats diseased tissue. Here’s the fascinating process:
- The Sound Focus: Doctors use specialized equipment to focus sound waves on a specific target in your body, much like using a magnifying glass to focus sunlight on a single point.
- The Bubble Effect: When these sound waves reach their target, they create thousands of microscopic bubbles. These aren’t just any bubbles – they’re smaller than the width of a human hair and exist for just microseconds.
- The Precision Break: These bubbles rapidly expand and collapse, creating tiny mechanical forces that break down unwanted tissue into a liquid state. It’s like transforming a solid piece of ice into water, but at a microscopic level.
- Real-Time Monitoring: The best part? Doctors can watch this entire process in real-time using standard ultrasound imaging, ensuring precise targeting throughout the procedure.
Why This Matters: The Game-Changing Benefits
What makes histotripsy particularly exciting for both doctors and patients?
- No Cutting Required: Unlike traditional surgery, there’s no need for incisions, meaning minimal risk of infection and faster recovery times.
- High Precision: The treatment can target areas as small as a grain of rice, protecting healthy tissue just millimeters away.
- Heat-Free Treatment: Unlike other treatments that burn tissue, histotripsy uses mechanical forces, reducing the risk of damage to surrounding areas.
- Quick Recovery: Most patients can go home the same day, with minimal post-procedure discomfort.
If you have cancer with metastasis to the liver, I suggest you investigate this as an option over other therapies.
The First International Experience with Histotripsy: A Safety Analysis of 230 Cases
This study, conducted between December 2022 and July 2024, represents the first real-world evidence of the treatment’s safety after its initial clinical trials.
The research followed 295 patients across 18 medical centers, treating a total of 510 liver tumors. These tumors originated from different types of cancer, including:
- Colorectal cancer (140 cases)
- Neuroendocrine tumors (46 cases)
- Liver cancer (31 cases)
- Pancreatic cancer (30 cases)
- Breast cancer that spread to the liver (26 cases)
Most patients received treatment for either one tumor (170 patients) or two tumors (69 patients) in their liver. Of the 230 patients with complete follow-up data, only 12 patients (5.2%) experienced complications, and most of these complications were minor. Sadly, three patients with advanced cancer who were receiving end-of-life care passed away, representing 1.3% of the study group.
These early results suggest that histotripsy could be a safer and effective option compared to other existing liver tumor treatments. 1
From Lab to Clinic: Real-World Applications
While histotripsy technology shows immense promise in laboratory settings, it’s also making significant strides in clinical applications. The THERESA trial, one of the first human studies of histotripsy for liver tumors, has demonstrated encouraging results. In this groundbreaking trial, researchers successfully used histotripsy to treat liver tumors with minimal side effects, marking a crucial step forward in bringing this technology to patients.
Several clinical trials are currently underway, including the HOPE4LIVER study across multiple European centers, which is evaluating the safety and effectiveness of histotripsy in treating both primary and metastatic liver cancers. Early results suggest that histotripsy could offer a viable alternative to traditional surgical approaches, particularly for patients who aren’t good candidates for surgery.
What makes these clinical applications particularly exciting is the potential ‘abscopal effect’. The word ‘abscopal’ is derived from Latin, with ‘ab’ meaning ‘away from’ and ‘scopus’ meaning ‘target.’ where treating one tumor site can trigger an immune response that affects cancer cells throughout the body. This suggests histotripsy might not just be a local treatment, but could potentially help fight metastatic cancer systemically.
If you would like to continue reading about this fascinating topic, here are some additional links on histotripsy:
Jan 31, 2023 – How sound waves trigger immune responses to cancer in mice
Jun 7, 2022 – 21st Annual International Symposium on Therapeutic Ultrasound (ISTU)
keynote speaker Zhen Xu https://istu.org/istu-2022-toronto/
April 18, 2022 – Tumors partially destroyed with sound don’t come back
March 6, 2022 – Prof. Zhen Xu won 2021-22 College of Engineering Rexford E. Hall
Innovation Excellence Award –
About the Author:
Donald R. Yance is the founder of the Mederi Center. A Clinical Master Herbalist and Certified Nutritionist, Donnie is renowned for his extraordinary knowledge and deep understanding of the healing properties of plants and nutrition, as well as of epigenetics, laboratory medicine, oncologic pathology, and molecular oncology. He is a professional member of the American Herbalists Guild, National Association of Nutrition Professionals, Academy of Integrative Health and Medicine, and the Society for Integrative Oncology.
References:
1 Wehrle CJ, Burns K, Ong E, Couillard A, Parikh ND, Caoili E, Kim J, Aucejo F, Schlegel A, Knott E, Laeseke P, Boudreaux JP, von Breitenbuch P, Silk M, Alassas M, Guzowski A, Fuller B, Koepsel EK, Hewitt B, Mendiratta-Lala M, Kwon CD. The First International Experience with Histotripsy: A Safety Analysis of 230 Cases. J Gastrointest Surg. 2025 Feb 18:102000. doi: 10.1016/j.gassur.2025.102000. Epub ahead of print. PMID: 39978577.
Xu, Z., Ludomirsky, A., Eun, L. Y., Hall, T. L., Tran, B. C., Fowlkes, J. B. & Cain, C. A.
Controlled ultrasound tissue erosion. IEEE Trans. Ultrason. Ferroelectr. Freq. Control 51, 726-736, (2004). PMC2669757
Maxwell, A. D., Wang, T. Y., Cain, C. A., Fowlkes, J. B., Sapozhnikov, O. A., Bailey, M.R. & Xu, Z. Cavitation clouds created by shock scattering from bubbles during histotripsy. The Journal of the Acoustical Society of America 130, 1888-1898, (2011). 3206907
Maxwell, A. D., Cain, C. A., Hall, T. L., Fowlkes, J. B. & Xu, Z. Probability of cavitation for single ultrasound pulses applied to tissues and tissue-mimicking materials. Ultrasound Med. Biol. 39, 449-465, (2013). 3570716
Vlaisavljevich, E., Maxwell, A., Mancia, L., Johnsen, E., Cain, C. & Xu, Z. Visualizing the Histotripsy Process: Bubble Cloud-Cancer Cell Interactions in a Tissue-Mimicking Environment. Ultrasound Med Biol 42, 2466-2477, (2016). PMC5010997
Parsons, J. E., Cain, C. A., Abrams, G. D. & Fowlkes, J. B. Pulsed cavitational ultrasound therapy for controlled tissue homogenization. Ultrasound Med Biol 32, 115- 129, (2006).
Worlikar, T., Mendiratta-Lala, M., Vlaisavljevich, E., Hubbard, R., Shi, J., Hall, T. L., Cho, C. S., Lee, F. T., Greve, J. & Xu, Z. Effects of Histotripsy on Local Tumor Progression in an in vivo Orthotopic Rodent Liver Tumor Model. BME Frontiers, (2020).
Worlikar, T., Zhang, M., Ganguly, A., Hall, T. L., Shi, J., Zhao, L., Lee, F. T., Mendiratta- Lala, M., Cho, C. S. & Xu, Z. Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model. Cancers (Basel) 14, 1612, (2022). PMC8996987
Styn, N. R., Hall, T. L., Fowlkes, J. B., Cain, C. A. & Roberts, W. W. Histotripsy of renal implanted VX-2 tumor in a rabbit model: investigation of metastases. Urology 80, 724- 729, (2012).
Owens, G. E., Miller, R. M., Ensing, G., Ives, K., Gordon, D., Ludomirsky, A. & Xu, Z. Therapeutic ultrasound to non-invasively create intracardiac communications in an intact animal model. Catheter Cardiovasc Interv. 77, 580-588, (2011). PMC3010446
Xu, Z., Owens, G., Gordon, D., Cain, C. A. & Ludomirsky, A. Non-invasive Creation of an Atrial Septal Defect by Histotripsy in a Canine Model. Circulation 121, 742-749, (2010). PMC2834201
Maxwell, A. D., Owens, G., Gurm, H. S., Ives, K., Myers, D. D., Jr. & Xu, Z. Noninvasive treatment of deep venous thrombosis using pulsed ultrasound cavitation therapy (histotripsy) in a porcine model. Journal of vascular and interventional radiology 22, 369-377, (2011). 3053086
Zhang, X., Macoskey, J. J., Ives, K., Owens, G. E., Gurm, H. S., Shi, J., Pizzuto, M., Cain, C. A. & Xu, Z. Non-Invasive Thrombolysis Using Microtripsy in a Porcine Deep Vein Thrombosis Model. Ultrasound Med Biol 43, 1378-1390, (2017). PMC5440202
Lu, N., Gupta, D., Daou, B. J., Fox, A., Choi, D., Sukovich, J. R., Hall, T. L., Camelo- Piragua, S., Chaudhary, N., Snell, J., Pandey, A. S., Noll, D. C. & Xu, Z. Transcranial Magnetic Resonance-Guided Histotripsy for Brain Surgery: Pre-clinical Investigation. Ultrasound Med Biol 48, 98-110, (2022).
Sukovich, J. R., Cain, C. A., Pandey, A. S., Chaudhary, N., Camelo-Piragua, S., Allen, S. P., Hall, T. L., Snell, J., Xu, Z., Cannata, J. M., Teofilovic, D., Bertolina, J. A., Kassell, N. & Xu, Z. In vivo histotripsy brain treatment. J Neurosurg, 1-8, (2018). PMC6925659
Gerhardson, T., Sukovich, J. R., Chaudhary, N., Chenevert, T. L., Ives, K., Hall, T. L., Camelo-Piragua, S., Xu, Z. & Pandey, A. S. Histotripsy Clot Liquefaction in a Porcine Intracerebral Hemorrhage Model. Neurosurgery 86, 429-436, (2020). PMC7308653
Qu, S., Worlikar, T., Felsted, A. E., Ganguly, A., Beems, M. V., Hubbard, R., Pepple, A. L., Kevelin, A. A., Garavaglia, H., Dib, J., Toma, M., Huang, H., Tsung, A., Xu, Z. & Cho, C. S. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. J Immunother Cancer 8, (2020). PMC7057529
Schade, G. R., Wang, Y. N., D’Andrea, S., Hwang, J. H., Liles, W. C. & Khokhlova, T. D. Boiling Histotripsy Ablation of Renal Cell Carcinoma in the Eker Rat Promotes a Systemic Inflammatory Response. Ultrasound Med Biol 45, 137-147, (2019). PMC6546431
Pepple, A. L., Guy, J. L., McGinnis, R., Felsted, A. E., Song, B., Hubbard, R., Worlikar, T., Garavaglia, H., Dib, J., Chao, H., Boyle, N., Olszewski, M., Xu, Z., Ganguly, A. & Cho, C. S. Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. Front Immunol 14, 1012799, (2023). PMC9900174
Schuster, T. G., Wei, J. T., Hendlin, K., Jahnke, R. & Roberts, W. W. Histotripsy Treatment of Benign Prostatic Enlargement Using the Vortx Rx System: Initial Human Safety and Efficacy Outcomes. Urology, (2018).
Vidal-Jove, J., Serres-Creixams, X., Ziemlewicz, T. J. & Cannata, J. M. Liver Histotripsy Mediated Abscopal Effect-Case Report. IEEE Trans Ultrason Ferroelectr Freq Control 68, 3001-3005, (2021).
Vidal-Jove, J., Serres, X., Vlaisavljevich, E., Cannata, J., Duryea, A., Miller, R., Merino, X., Velat, M., Kam, Y., Bolduan, R., Amaral, J., Hall, T., Xu, Z., Lee, F. T., Jr. & Ziemlewicz, T. J. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int. J. Hyperthermia 39, 1115-1123, (2022).
Wang YB, Zeng HS, Salameen H, Miao CM, Chen L, Ding X. High-intensity focused ultrasound versus transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Int J Radiat Biol. 2023 Jul 31:1-11. doi: 10.1080/09553002.2023.2232009. PMID: 37523652
Liao M, Chen F, Chen L, Wu Z, Huang J, Pang H, Cheng C, Wu Z, Ma L, Lu Q. Synergistic Enzyme-Mimetic Catalysis-Based Non-Thermal Sonocavitation and Sonodynamic Therapy for Efficient Hypoxia Relief and Cancer Ablation. Small. 2023 Jun 15:e2302744. doi: 10.1002/smll.202302744. PMID: 37322373
Haram M, Hansen R, Bouget D, Myhre OF, Davies CL, Hofsli E. Treatment of Liver Metastases With Focused Ultrasound and Microbubbles in Patients With Colorectal Cancer Receiving Chemotherapy. Ultrasound Med Biol. 2023 Jun 17:S0301-5629(23)00171-0. doi: 10.1016/j.ultrasmedbio.2023.05.013. PMID: 37336691
Dupré A, Rivoire M, Metzger S, Cropet C, Vincenot J, Peyrat P, Chen Y, Pérol D, Melodelima D. Intra-operative High-Intensity Focused Ultrasound in Patients With Colorectal Liver Metastases: A Prospective Ablate-and-Resect Study. Ultrasound Med Biol. 2023 Aug;49(8):1845-1851. doi: 10.1016/j.ultrasmedbio.2023.04.010. Epub 2023 May 31. PMID: 37268553
Wang J, Wan L, Huang G, Chen C, Wu Y. Comparison of high-intensity focused ultrasound and microwave ablation for the treatment of small liver metastatic tumors. J Int Med Res. 2023 Apr;51(4):3000605231165551. doi: 10.1177/03000605231165551.
Zou YW, Ren ZG, Sun Y, Liu ZG, Hu XB, Wang HY, Yu ZJ. The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2023 Feb;22(1):54-63. doi: 10.1016/j.hbpd.2022.08.004. Epub 2022 Aug 19.
Wah TM, Pech M, Thormann M, Serres X, Littler P, Stenberg B, Lenton J, Smith J, Wiggermann P, Planert M, Vidal-Jove J, Torzilli G, Solbiati L. A Multi-centre, Single Arm, Non-randomized, Prospective European Trial to Evaluate the Safety and Efficacy of the HistoSonics System in the Treatment of Primary and Metastatic Liver Cancers (#HOPE4LIVER). Cardiovasc Intervent Radiol. 2023 Feb;46(2):259-267. doi: 10.1007/s00270-022-03309-6. Epub 2022 Nov 15.
Mauch SC, Zlevor AM, Knott EA, Couillard AB, Periyasamy S, Williams EC, Swietlik JF, Laeseke PF, Zhang X, Xu Z, Abel EJ, Lee FT Jr, Ziemlewicz TJ. Hepatic and Renal Histotripsy in an Anticoagulated Porcine Model. J Vasc Interv Radiol. 2023 Mar;34(3):386-394.e2. doi: 10.1016/j.jvir.2022.11.034. Epub 2022 Dec 9.
Xiao C, Liu S, Ge G, Jiang H, Wang L, Chen Q, Jin C, Mo J, Li J, Wang K, Zhang Q, Zhou J. Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies. Front Pharmacol. 2023 Feb 6;14:1086813. doi: 10.3389/fphar.2023.1086813. eCollection 2023.
Froghi S, de Andrade MO, Hadi LM, Gelat P, Rashidi H, Quaglia A, Fuller B, Saffari N, Davidson B. Liver Ultrasound Histotripsy: Novel Analysis of the Histotripsy Site Cell Constituents with Implications for Histotripsy Application in Cell Transplantation and Cancer Therapy. Bioengineering (Basel). 2023 Feb 20;10(2):276. doi: 10.3390/bioengineering10020276.
Robinson TP, Pebror T, Krosin ME, Koniaris LG. Ablative Therapy in Non-HCC Liver Malignancy. Cancers (Basel). 2023 Feb 14;15(4):1200. doi: 10.3390/cancers15041200.
Cambronero S, Dupré A, Mastier C, Melodelima D. Non-invasive High-Intensity Focused Ultrasound Treatment of Liver Tissues in an In Vivo Porcine Model: Fast, Large and Safe Ablations Using a Toroidal Transducer. Ultrasound Med Biol. 2023 Jan;49(1):212-224. doi: 10.1016/j.ultrasmedbio.2022.08.015. Epub 2022 Oct 28.
Elfatairy K. First-In-Human Histotripsy Trial for Liver Tumor Treatment: The New Echo Superpower. Radiol Imaging Cancer. 2023 Jan;5(1):e229026. doi: 10.1148/rycan.229026.
Tang X, He X, Jiang H. Efficacy and safety of HIFU in combination with TACE in unresectable pediatric HB: A randomized, controlled, single-center clinical trial. Medicine (Baltimore). 2022 Dec 2;101(48):e32022. doi: 10.1097/MD.0000000000032022.
Guntur SR, Kim SC, Choi MJ. A Cost-Effective Reusable Tissue Mimicking Phantom for High Intensity Focused Ultrasonic Liver Surgery. Bioengineering (Basel). 2022 Dec 9;9(12):786. doi: 10.3390/bioengineering9120786.
Zou X, Li T, Mao Y, Zhu M, Chen X, Niu J, Dong T, Jiang J, Yang X. Multifunctional Drug-Loaded Phase-Change Nanoparticles Inhibit the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Affecting the Activity of Activated Hepatic Stellate Cells. Biomed Res Int. 2022 Nov 12;2022:6441179. doi: 10.1155/2022/6441179. eCollection 2022.
Knott EA, Zlevor AM, Hinshaw JL, Laeseke PF, Longhurst C, Frank J, Bradley CW, Couillard AB, Rossebo AE, Xu Z, Lee FT Jr, Ziemlewicz TJ. A comparison study of microwave ablation vs. histotripsy for focal liver treatments in a swine model. Eur Radiol. 2022 Sep 1. doi: 10.1007/s00330-022-09112-8.
Shi S, Li H, Zheng X, Lv L, Liao S, Lu P, Liu M, Zhao H, Mei Z. Visualization system based on hierarchical targeting for diagnosis and treatment of hepatocellular carcinoma. Mater Today Bio. 2022 Aug 22;16:100398. doi: 10.1016/j.mtbio.2022.100398. eCollection 2022 Dec.
Heo J, Joung C, Pahk K, Pahk KJ. Investigation of the long-term healing response of the liver to boiling histotripsy treatment in vivo. Sci Rep. 2022 Aug 24;12(1):14462. doi: 10.1038/s41598-022-18544-7.
Zhang L, Qiao L, Zhang M, Xue Y, Zhang X, Gao X. Comparison of prognosis among patients with colorectal cancer liver metastases treated by surgical resection, radiofrequency ablation and HIFU: A protocol for network meta-analysis. Medicine (Baltimore). 2022 Aug 19;101(33):e27915. doi: 10.1097/MD.0000000000027915.
Finotti M, Romano M, Brizzolari M, Scopelliti M, Zanus G. Comment on: “A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis”. Hepatobiliary Surg Nutr. 2022 Aug;11(4):640-642. doi: 10.21037/hbsn-22-202.
Ozen M, Raissi D. Editorial comment: a review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis. Hepatobiliary Surg Nutr. 2022 Jun;11(3):453-456. doi: 10.21037/hbsn-22-138.
Zhang JY, Chen L, Ma R, Miao CM, Wang YB. Effectiveness and safety of focused ultrasound ablation surgery compared with radiofrequency ablation in primary hepatocellular carcinoma treatment: a meta-analysis. Transl Cancer Res. 2021 May;10(5):2080-2090. doi: 10.21037/tcr-20-3458.
Tsang SH, Ma KW, She WH, Chu F, Lau V, Lam SW, Cheung TT, Lo CM. High-intensity focused ultrasound ablation of liver tumors in difficult locations. Int J Hyperthermia. 2021 Sep;38(2):56-64. doi: 10.1080/02656736.2021.1933217.
Merrill R, Odéen H, Dillon C, Bitton R, Ghanouni P, Payne A. Design and evaluation of an open-source, conformable skin-cooling system for body magnetic resonance guided focused ultrasound treatments. Int J Hyperthermia. 2021;38(1):679-690. doi: 10.1080/02656736.2021.1914872.
Barrere V, Sanchez M, Cambronero S, Dupré A, Rivoire M, Melodelima D. Evaluation of Ultrasonic Attenuation in Primary and Secondary Human Liver Tumors and Its Potential Effect on High-Intensity Focused Ultrasound Treatment. Ultrasound Med Biol. 2021 Apr 21:S0301-5629(21)00135-6. doi: 10.1016/j.ultrasmedbio.2021.03.014.
Hendricks A, Weber P, Simon A, Saunier S, Coutermarsh-Ott S, Grider D, Jove JV, Allen IC, Luyimbazi D, Vlaisavljevich E. Histotripsy for the Treatment of Cholangiocarcinoma Liver Tumors: In Vivo Feasibility and Ex Vivo Dosimetry Study. IEEE Trans Ultrason Ferroelectr Freq Control. 2021 Apr 15;PP. doi: 10.1109/TUFFC.2021.3073563.
Gu L, Shen Z, Ji L, Ng DM, Du N, He N, Fan X, Yan K, Zheng Z, Chen B, Ma L, Qiu G, Chen P, Zheng J, Yang T. High-intensity focused ultrasound alone or combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with unsuitable indications for hepatectomy and radiofrequency ablation: a phase II clinical trial. Surg Endosc. 2021 Mar 31. doi: 10.1007/s00464-021-08465-3.